Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer

By Matthew R. Smith, F. Saad, S. Chowdhury, S. Oudard, B. Hadaschik, J. Graff, D. Olmos, P. Mainwaring, J. Lee, H. Uemura and 8 more. New England Journal of Medicine, 2018

1,111 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/57bb3a21842c65159bc277c6b069d2c4a96028d6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. N. Mottet
2. Thomas Wiegel

In Pulmonary and Respiratory Medicine

1. N. Mottet
2. Thomas Wiegel

Citations in the corpus

• EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. (2020, background): “Three large randomised controlled phase III trials, SPARTAN [98], PROSPER [99], and ARAMIS [100], evaluated metastasis-free survival as the primary end point in patients with nonmetastatic CRPC (M0 CRPC) treated with the addition of a modern antiandrogen to ADT.”